Enriched eggs to improve eye health in people with Type 2 diabetes
Effects of DHA and Lutein Enriched Eggs on Retina Health and Metabolic and Physical Parameters in Type 2 Diabetes: a Strategy for Diabetic Retinopathy
This study is testing if eating special eggs with added nutrients can help protect the eyes of adults with Type 2 diabetes from damage that could lead to vision problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | University of Manitoba Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Winnipeg, Manitoba) |
| Trial ID | NCT04496817 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of consuming docosahexaenoic acid and lutein enriched eggs on retinal health in adults with Type 2 diabetes. It aims to determine whether these enriched eggs can help prevent the onset of diabetic retinopathy, a common complication of diabetes that can lead to blindness. Participants will be adults over 19 years old who are diagnosed with Type 2 diabetes and are taking specific oral medications. The study will compare the effects of enriched eggs against regular eggs on visual function and eye health.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 19 years old diagnosed with Type 2 diabetes who are taking oral hypoglycemic medications.
Not a fit: Patients with moderate to severe diabetic retinopathy or other significant eye diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a dietary intervention to help prevent diabetic retinopathy in individuals with Type 2 diabetes.
How similar studies have performed: While there is ongoing research into dietary interventions for diabetic retinopathy, this specific approach using enriched eggs is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (\>19 years of age) * Individuals diagnosed with Type 2 diabetes * Individuals taking oral hypoglycemic medications (sulfonylureas, meglitinides, biguanides, thiazolidinediones etc.) * Individuals with a fasting plasma glucose of ≥7.0 mmol/L or glycated hemoglobin (A1C) of ≥6.5%. (these values are based on the Canadian Diabetes Association and are predictors of the development of diabetic retinopathy) Exclusion Criteria: * Individuals previously diagnosed with moderate to severe diabetic retinopathy (to assess egg consumption as a preventative strategy for diabetic retinopathy). * Individuals with eye disease (cataracts, glaucoma, age-related macular degeneration, retinitis pigmentosa, optic atrophy, and eye malformation etc.) * Individuals with Alzheimer's, dementia or other mental cognitive diseases * Individuals with Type 1 diabetes * Individuals taking insulin * Individuals diagnosed with cancer or anemia * Pregnant women
Where this trial is running
Winnipeg, Manitoba
- Asper Clinical Research Institute — Winnipeg, Manitoba, Canada (Recruiting)
Study contacts
- Principal investigator: Miyoung Suh, RD, PhD — University of Manitoba
- Study coordinator: Miyoung Suh, RD, PhD
- Email: miyoung.suh@umanitoba.ca
- Phone: 204-235-3106
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.